CA2928708A1 - Endoglin peptides to treat fibrotic diseases - Google Patents

Endoglin peptides to treat fibrotic diseases Download PDF

Info

Publication number
CA2928708A1
CA2928708A1 CA2928708A CA2928708A CA2928708A1 CA 2928708 A1 CA2928708 A1 CA 2928708A1 CA 2928708 A CA2928708 A CA 2928708A CA 2928708 A CA2928708 A CA 2928708A CA 2928708 A1 CA2928708 A1 CA 2928708A1
Authority
CA
Canada
Prior art keywords
eng
seq
amino acid
heng
hfc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2928708A
Other languages
English (en)
French (fr)
Inventor
Asya Grinberg
Roselyne CASTONGUAY
Eric Werner
Ravindra Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA2928708A1 publication Critical patent/CA2928708A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2928708A 2013-10-25 2014-10-24 Endoglin peptides to treat fibrotic diseases Abandoned CA2928708A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361896002P 2013-10-25 2013-10-25
US61/896,002 2013-10-25
PCT/US2014/062147 WO2015061666A1 (en) 2013-10-25 2014-10-24 Endoglin peptides to treat fibrotic diseases

Publications (1)

Publication Number Publication Date
CA2928708A1 true CA2928708A1 (en) 2015-04-30

Family

ID=51894230

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2928708A Abandoned CA2928708A1 (en) 2013-10-25 2014-10-24 Endoglin peptides to treat fibrotic diseases

Country Status (9)

Country Link
US (2) US20150202260A1 (cg-RX-API-DMAC7.html)
EP (2) EP3851118A1 (cg-RX-API-DMAC7.html)
JP (3) JP6546587B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220013459A (cg-RX-API-DMAC7.html)
CN (1) CN105899225A (cg-RX-API-DMAC7.html)
AU (2) AU2014339898B2 (cg-RX-API-DMAC7.html)
CA (1) CA2928708A1 (cg-RX-API-DMAC7.html)
EA (2) EA202090707A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015061666A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
AU2012245439B2 (en) 2011-04-20 2017-04-06 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
CN105899225A (zh) 2013-10-25 2016-08-24 阿塞勒隆制药公司 用于治疗纤维化疾病的内皮联蛋白肽
WO2016193872A2 (en) * 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
WO2018009624A1 (en) * 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
CN106994181A (zh) * 2017-03-10 2017-08-01 上海交通大学医学院附属第九人民医院 Bmp9在制备延缓肝纤维化药物中的应用
WO2020022438A1 (ja) * 2018-07-26 2020-01-30 参天製薬株式会社 網膜線維化を伴う眼疾患の処置剤
CN114630662B (zh) * 2020-10-08 2025-04-04 科罗姆生物科技有限公司 包含β-拉帕醌作为有效成分的用于预防或治疗胆汁淤积性肝病的药学组合物
KR20240167591A (ko) * 2023-05-18 2024-11-27 한국과학기술연구원 항-엔도글린 항체 및 이의 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
AU5541094A (en) 1992-10-30 1994-05-24 Consejo Superior De Investigaciones Cientificas Compositions and methods for modifying the regulatory activity of tgf-beta
US5830847A (en) * 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
SI1325932T1 (cg-RX-API-DMAC7.html) 1997-04-07 2005-08-31 Genentech Inc
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP1695985B1 (en) 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU7467898A (en) 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
KR20080068151A (ko) 2000-06-23 2008-07-22 바이엘 쉐링 파마 악티엔게젤샤프트 ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1638941B1 (en) 2003-05-22 2010-06-02 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20090170767A1 (en) 2006-05-31 2009-07-02 Beth Israel Deaconess Medical Center Soluble Endoglin Compounds for the Treatment and Prevention of Cancer
US20090286271A1 (en) 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
EP3181580A1 (en) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
WO2008151078A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
US20100210713A1 (en) * 2009-01-16 2010-08-19 The General Hospital Corporation Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP3384964B1 (en) * 2009-03-30 2020-03-25 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
WO2010128158A1 (en) 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders
US8795663B2 (en) 2010-01-12 2014-08-05 Beth Israel Deaconess Medical Center, Inc. Soluble endoglin and uses thereof
AU2012245439B2 (en) 2011-04-20 2017-04-06 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
WO2013019805A1 (en) * 2011-08-01 2013-02-07 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
CA2962277C (en) * 2013-09-20 2021-12-07 Tufts Medical Center, Inc. Methods and compositions for reducing cardiac damage and other conditions
CN105899225A (zh) 2013-10-25 2016-08-24 阿塞勒隆制药公司 用于治疗纤维化疾病的内皮联蛋白肽
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof

Also Published As

Publication number Publication date
KR102354787B1 (ko) 2022-01-24
EA035481B1 (ru) 2020-06-23
AU2014339898B2 (en) 2020-07-23
KR20160066553A (ko) 2016-06-10
AU2020244463A1 (en) 2020-10-29
US20150202260A1 (en) 2015-07-23
JP2019196364A (ja) 2019-11-14
JP6546587B2 (ja) 2019-07-17
JP6994481B2 (ja) 2022-02-04
EP3060235A1 (en) 2016-08-31
EA202090707A1 (ru) 2020-12-30
WO2015061666A1 (en) 2015-04-30
EA201690855A1 (ru) 2016-10-31
JP2022058352A (ja) 2022-04-12
JP2016535741A (ja) 2016-11-17
EP3060235B1 (en) 2020-12-02
KR20220013459A (ko) 2022-02-04
AU2014339898A1 (en) 2016-05-26
US11590201B2 (en) 2023-02-28
CN105899225A (zh) 2016-08-24
US20200164029A1 (en) 2020-05-28
EP3851118A1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
US10981972B2 (en) Endoglin polypeptides and uses thereof
US11590201B2 (en) Endoglin peptides to treat fibrotic diseases
US20210002342A1 (en) Bmprii polypeptides and uses thereof
HK40055818A (en) Endoglin peptides to treat fibrotic diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191011

EEER Examination request

Effective date: 20191011

EEER Examination request

Effective date: 20191011

EEER Examination request

Effective date: 20191011

FZDE Discontinued

Effective date: 20231229